Corcept Therapeutics Stock Merits Accumulation [Seeking Alpha]
![Seeking Alpha](../../../Content/images/providers/Seeking Alpha.png)
Corcept Therapeutics Incorporated (CORT)
Last corcept therapeutics incorporated earnings: 2/20 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
corcept.com/investors
Company Research
Source: Seeking Alpha
However, the company is preparing an NDA for Korlym's successor, which could be approved for all etiologies of Cushing's syndrome. Corcept also has multiple clinical trials readouts expected in 2024 and a strong balance sheet, making it the stock worthy of accumulation. An updated analysis around Corcept Therapeutics follows in the paragraphs below. Looking for more investing ideas like this one? Get them exclusively at The Biotech Forum. Learn More » Shares of cortisol concern Corcept Therapeutics Incorporated ( NASDAQ: CORT were initially suppressed after a court found that Teva's (TEVA) generic would not infringe on its Korlym's (mifepristone) patents. The shares have acted much better recently, it should be noted. This has prompted a revisit since our last article on this name almost four months ago. While a decision on the appeal is likely not due until 2025, the company is prepping an NDA for Korlym's successor, which could be approved for all etiologies of Cushing's
Show less
Read more
Impact Snapshot
Event Time:
CORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CORT alerts
High impacting Corcept Therapeutics Incorporated news events
Weekly update
A roundup of the hottest topics
CORT
News
- Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association's Scientific Sessions [Yahoo! Finance]Yahoo! Finance
- Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific SessionsGlobeNewswire
- What Makes Corcept Therapeutics (CORT) a Good Investment Bet? [Yahoo! Finance]Yahoo! Finance
- Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $65.00 price target on the stock.MarketBeat
- Corcept Therapeutics Incorporated (NASDAQ: CORT) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $65.00 price target on the stock, up previously from $44.00.MarketBeat
CORT
Earnings
- 5/1/24 - Beat
CORT
Sec Filings
- 6/24/24 - Form 4
- 6/6/24 - Form 4
- 6/5/24 - Form 4
- CORT's page on the SEC website